[Medical treatment options in BRCA-associated cancers]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Germline or somatic mutations in BRCA genes are key therapeutic targets.
• BRCA gene dysfunction sensitizes cancers to DNA-targeting agents and PARP inhibitors.
• BRCA mutations are found in various cancers, but specific therapies are effective mainly in BRCA-associated cancers.

Purpose of the Study:

• To review the role of BRCA mutations as therapeutic targets.
• To discuss the efficacy of DNA-targeted chemotherapy and PARP inhibitors in BRCA-associated cancers.
• To highlight the types of BRCA mutations (germline/somatic) relevant to different cancer types.

Main Methods:

• Literature review of BRCA mutations and associated therapies.
• Analysis of therapeutic efficacy in ovarian, breast, pancreatic, prostate cancers, and uterine sarcomas.
• Examination of platinum sensitivity as a biomarker for DNA repair deficiency.

Main Results:

• BRCA mutations are crucial in ovarian, breast, pancreatic, and prostate cancers, and uterine sarcomas.
• Germline BRCA mutations are common in breast and pancreatic cancers, while both germline and somatic mutations are relevant in ovarian and prostate cancers.
• Somatic mutations are predominant in uterine sarcomas; platinum sensitivity can indicate DNA repair deficiency in ovarian cancer.

Conclusions:

• BRCA mutations represent significant therapeutic targets in specific malignancies.
• Platinum-based chemotherapy and PARP inhibitors offer effective treatment strategies for BRCA-dependent cancers.
• PARP inhibitors have transformed ovarian cancer treatment and provide options for other BRCA-associated cancers.